Answers are grounded in this paper and cite their sources.
A bstract Background: Depression among gynecological cancer patients can significantly impact treatment outcomes and overall quality of life. Objective: This study aimed to determine the prevalence of depressive disorders and their associated factors among gynecological cancer patients in Enugu, South-East Nigeria. Materials and Methods: A hospital-based cross-sectional descriptive study was conducted among 197 gynecological cancer patients attending the Gynaecological Oncology Unit of the University of Nigeria Teaching Hospital, Enugu, between January 2 and May 31, 2022. The hospital anxiety and depression scale was used to assess depressive disorders. Data were analyzed using the Statistical Package for the Social Sciences (IBM SPSS, Armonk, New York, USA) version 24.0. Categorical variables were analyzed using the chi-square test, while logistic regression was employed to identify factors associated with depression. Results: The distribution of cancers among participants was as follows: cervical (56.3%), ovarian (17.3%), endometrial (14.2%), vulvar (7.2%), and choriocarcinoma (5.1%). A majority of patients (78.2%) presented with late-stage disease. The overall prevalence of depression was 25.4%. Depression was most prevalent among patients with vulvar cancer (42.9%) and ovarian cancer (41.2%), followed by cervical (24.3%) and endometrial cancers (10.7%). Younger age (<40 years) (p = 0.009) and late-stage disease (p = 0.041) were significantly associated with depression. Conclusion: The prevalence of depression among gynecological cancer patients in this setting was high. These findings underscore the importance of routine depression screening and the integration of appropriate mental health interventions into the care of gynecological cancer patients.
No takes yet. Share an insight, caveat, or question.
Ajah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: